RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse
Authors:
Open Access
- 1 September 2021
- journal article
- research article
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 108, 106482
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca plc
- Cancer Research UK
This publication has 24 references indexed in Scilit:
- Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell CarcinomaJournal of Clinical Oncology, 2017
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung CancerNew England Journal of Medicine, 2017
- Adjuvant Treatment for High-Risk Clear Cell Renal CancerJAMA Oncology, 2017
- Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after NephrectomyNew England Journal of Medicine, 2016
- Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based studyWorld Journal of Urology, 2016
- The Role of Adrenalectomy in Renal CancerEuropean Urology Focus, 2016
- Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2015
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter StudyJournal of Clinical Oncology, 2009
- POSTOPERATIVE SURVEILLANCE PROTOCOL FOR PATIENTS WITH LOCALIZED AND LOCALLY ADVANCED RENAL CELL CARCINOMA BASED ON A VALIDATED PROGNOSTIC NOMOGRAM AND RISK GROUP STRATIFICATION SYSTEMJournal of Urology, 2005
- Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinomaCancer, 2003